Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mélanie Mecteau is active.

Publication


Featured researches published by Mélanie Mecteau.


British Journal of Pharmacology | 2009

Regression of aortic valve stenosis by ApoA-I mimetic peptide infusions in rabbits.

Busseuil D; Yanfen Shi; Mélanie Mecteau; Geneviève Brand; Anne-Elen Kernaleguen; Eric Thorin; Jean-Gilles Latour; Eric Rhéaume; Jean-Claude Tardif

Aortic valve stenosis (AVS) is the most common valvular heart disease, and standard curative therapy remains open heart surgical valve replacement. The aim of our experimental study was to determine if apolipoprotein A‐I (ApoA‐I) mimetic peptide infusions could induce regression of AVS.


The Cardiology | 2010

Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis.

David Busseuil; Yanfen Shi; Mélanie Mecteau; Geneviève Brand; Marc-Antoine Gillis; Eric Thorin; Caroline Asselin; Philippe Romeo; Tack Ki Leung; Jean-Gilles Latour; Christine Des Rosiers; Muriel Bouly; Eric Rhéaume; Jean-Claude Tardif

Objectives: To determine if heart rate (HR) reduction with ivabradine (IVA), a selective inhibitor of the pacemaker If current, prevents cardiac dysfunction associated with dyslipidemia. Methods: New Zealand White rabbits received either a standard diet, a 0.5% cholesterol-enriched diet only (CD), or a 0.5% CD with IVA (17 mg/kg/day) for 12 weeks. HR, left ventricular (LV) systolic function, diastolic function and LV regional myocardial performance index (MPI) were studied using echocardiography. Histological analysis included cardiac interstitial fibrosis and collagen type I fibers. Plasma levels of angiotensin II and aldosterone were quantified by immunoassays. Results: IVA reduced HR by approximately 11%. IVA improved MPI and attenuated LV diastolic dysfunction (DD) (92% mild and 8% moderate DD with IVA vs. 54% mild and 46% moderate DD in CD group). IVA also reduced atrial fibrosis (p = 0.027), ventricular fibrosis (p = 0.0002) and ventricular collagen type I (p = 0.0042). IVA decreased plasma angiotensin II levels (p = 0.042), and both angiotensin II and aldosterone levels were correlated with HR (p = 0.038 and 0.008). Conclusion: Selective HR reduction with IVA reduces DD and cardiac fibrosis in hypercholesterolemic rabbits. These beneficial effects of IVA support testing pure HR reduction in patients with diastolic heart failure.


British Journal of Pharmacology | 2013

Improvement of aortic valve stenosis by ApoA‐I mimetic therapy is associated with decreased aortic root and valve remodelling in mice

Trapeaux J; Busseuil D; Yanfen Shi; Nobari S; Shustik D; Mélanie Mecteau; El-Hamamsy I; Lebel M; Mongrain R; Eric Rhéaume; Jean-Claude Tardif

We have shown that infusions of apolipoprotein A‐I (ApoA‐I) mimetic peptide induced regression of aortic valve stenosis (AVS) in rabbits. This study aimed at determining the effects of ApoA‐I mimetic therapy in mice with calcific or fibrotic AVS.


Biomedical Optics Express | 2015

Validating a bimodal intravascular ultrasound (IVUS) and near-infrared fluorescence (NIRF) catheter for atherosclerotic plaque detection in rabbits.

Maxime Abran; Barbara E. Stähli; Nolwenn Merlet; Teodora Mihalache-Avram; Mélanie Mecteau; Eric Rhéaume; David Busseuil; Jean-Claude Tardif; Frédéric Lesage

Coronary artery disease is characterized by atherosclerotic plaque formation. Despite impressive advances in intravascular imaging modalities, in vivo molecular plaque characterization remains challenging, and different multimodality imaging systems have been proposed. We validated an engineered bimodal intravascular ultrasound imaging (IVUS) / near-infrared fluorescence (NIRF) imaging catheter in vivo using a balloon injury atherosclerosis rabbit model. Rabbit aortas and right iliac arteries were scanned in vivo after indocyanine green (ICG) injection, and compared to corresponding ex vivo fluorescence and white light images. Areas of ICG accumulation were colocalized with macroscopic atherosclerotic plaque formation. In vivo imaging was performed with the bimodal catheter integrating ICG-induced fluorescence signals into cross-sectional IVUS imaging. In vivo ICG accumulation corresponded to ex vivo fluorescence signal intensity and IVUS identified plaques.


PLOS ONE | 2014

Optimisation of reference genes for gene-expression analysis in a rabbit model of left ventricular diastolic dysfunction.

Walid Nachar; David Busseuil; Yanfen Shi; Teodora Mihalache-Avram; Mélanie Mecteau; Eric Rhéaume; Jean-Claude Tardif

Left ventricular diastolic dysfunction (LVDD) is characterized by the disturbance of ventricle’s performance due to its abnormal relaxation or to its increased stiffness during the diastolic phase. The molecular mechanisms underlying LVDD remain unknown. We aimed to identify normalization genes for accurate gene-expression analysis of LVDD using quantitative real-time PCR (RT-PCR) in a new rabbit model of LVDD. Eighteen rabbits were fed with a normal diet (n = 7) or a 0.5% cholesterol-enriched diet supplemented with vitamin D2 (n = 11) for an average of 14.5 weeks. We validated the presence of LVDD in this model using echocardiography for diastolic function assessment. RT-PCR was performed using cDNA derived from left ventricle samples to measure the stability of 10 genes as candidate reference genes (Gapdh, Hprt1, Ppia, Sdha, Rpl5, Actb, Eef1e1, Ywhaz, Pgk1, and G6pd). Using geNorm analysis, we report that Sdha, Gapdh and Hprt1 genes had the highest stability (M <0.2). By contrast, Hprt1 and Rpl5 genes were found to represent the best combination for normalization when using the Normfinder algorithm (stability value of 0.042). Comparison of both normalization strategies highlighted an increase of natriuretic peptides (Bnp and Anp), monocytes chemotactic protein-1 (Mcp-1) and NADPH oxidase subunit (Nox-2) mRNA expressions in ventricle samples of the hypercholesterolemic rabbits compared to controls (P<0.05). This increase correlates with LVDD echocardiographic parameters and most importantly it molecularly validates the presence of the disease in our model. This is the first study emphasizing the selection of stable reference genes for RT-PCR normalization in a rabbit model of LVDD.


International Journal of Molecular Sciences | 2016

Validating Intravascular Imaging with Serial Optical Coherence Tomography and Confocal Fluorescence Microscopy

Pier-Luc Tardif; Marie-Jeanne Bertrand; Maxime Abran; Alexandre Castonguay; Joël Lefebvre; Barbara E. Stähli; Nolwenn Merlet; Teodora Mihalache-Avram; Pascale Geoffroy; Mélanie Mecteau; David Busseuil; Feng Ni; Abedelnasser Abulrob; Eric Rhéaume; Philippe L. L’Allier; Jean-Claude Tardif; Frédéric Lesage

Atherosclerotic cardiovascular diseases are characterized by the formation of a plaque in the arterial wall. Intravascular ultrasound (IVUS) provides high-resolution images allowing delineation of atherosclerotic plaques. When combined with near infrared fluorescence (NIRF), the plaque can also be studied at a molecular level with a large variety of biomarkers. In this work, we present a system enabling automated volumetric histology imaging of excised aortas that can spatially correlate results with combined IVUS/NIRF imaging of lipid-rich atheroma in cholesterol-fed rabbits. Pullbacks in the rabbit aortas were performed with a dual modality IVUS/NIRF catheter developed by our group. Ex vivo three-dimensional (3D) histology was performed combining optical coherence tomography (OCT) and confocal fluorescence microscopy, providing high-resolution anatomical and molecular information, respectively, to validate in vivo findings. The microscope was combined with a serial slicer allowing for the imaging of the whole vessel automatically. Colocalization of in vivo and ex vivo results is demonstrated. Slices can then be recovered to be tested in conventional histology.


International Journal of Cardiology | 2016

HDL mimetic peptide CER-522 treatment regresses left ventricular diastolic dysfunction in cholesterol-fed rabbits

Nolwenn Merlet; David Busseuil; Teodora Mihalache-Avram; Mélanie Mecteau; Yanfen Shi; Walid Nachar; Geneviève Brand; Mathieu R. Brodeur; Daniel Charpentier; David Rhainds; Gavin Sy; Anna Schwendeman; Narendra D. Lalwani; Jean Louis Dasseux; Eric Rhéaume; Jean-Claude Tardif

OBJECTIVES High-density lipoprotein (HDL) infusions induce rapid improvement of experimental atherosclerosis in rabbits but their effect on ventricular function remains unknown. We aimed to evaluate the effects of the HDL mimetic peptide CER-522 on left ventricular diastolic dysfunction (LVDD). METHODS Rabbits were fed with a cholesterol- and vitamin D2-enriched diet until mild aortic valve stenosis and hypercholesterolemia-induced LV hypertrophy and LVDD developed. Animals then received saline or 10 or 30mg/kg CER-522 infusions 6 times over 2weeks. We performed serial echocardiograms and LV histology to evaluate the effects of CER-522 therapy on LVDD. RESULTS LVDD was reduced by CER-522 as shown by multiple parameters including early filling mitral deceleration time, deceleration rate, Em/Am ratio, E/Em ratio, pulmonary venous velocities, and LVDD score. These findings were associated with reduced macrophages (RAM-11 positive cells) in the pericoronary area and LV, and decreased levels of apoptotic cardiomyocytes in CER-522-treated rabbits. CER-522 treatment also resulted in decreased atheromatous plaques and internal elastic lamina area in coronary arteries. CONCLUSIONS CER-522 improves LVDD in rabbits, with reductions of LV macrophage accumulation, cardiomyocyte apoptosis, coronary atherosclerosis and remodelling.


Circulation | 2018

Adenylate Cyclase Type 9 (ADCY9) Inactivation Protects from Atherosclerosis Only in the Absence of Cholesteryl Ester Transfer Protein (CETP)

Yohann Rautureau; Vanessa Deschambault; Marie-Ève Higgins; Daniel Rivas; Mélanie Mecteau; Pascale Geoffroy; Géraldine Miquel; Kurunradeth Uy; Rocio Sanchez; Véronique Lavoie; Geneviève Brand; Audrey Nault; Pierre-Marc Williams; Maria Laura Suarez; Nolwenn Merlet; Line Lapointe; Natacha Duquette; Marc-Antoine Gillis; Samaneh Samami; Gaétan Mayer; Philippe Pouliot; Adeline Raignault; Foued Maafi; Mathieu R. Brodeur; Sylvie Levesque; Marie-Claude Guertin; Marie-Pierre Dubé; Eric Thorin; David Rhainds; Eric Rhéaume

Background: Pharmacogenomic studies have shown that ADCY9 genotype determines the effects of the CETP (cholesteryl ester transfer protein) inhibitor dalcetrapib on cardiovascular events and atherosclerosis imaging. The underlying mechanisms responsible for the interactions between ADCY9 and CETP activity have not yet been determined. Methods: Adcy9-inactivated (Adcy9Gt/Gt) and wild-type (WT) mice, that were or not transgenic for the CETP gene (CETPtgAdcy9Gt/Gt and CETPtgAdcy9WT), were submitted to an atherogenic protocol (injection of an AAV8 [adeno-associated virus serotype 8] expressing a PCSK9 [proprotein convertase subtilisin/kexin type 9] gain-of-function variant and 0.75% cholesterol diet for 16 weeks). Atherosclerosis, vasorelaxation, telemetry, and adipose tissue magnetic resonance imaging were evaluated. Results: Adcy9Gt/Gt mice had a 65% reduction in aortic atherosclerosis compared to WT (P<0.01). CD68 (cluster of differentiation 68)-positive macrophage accumulation and proliferation in plaques were reduced in Adcy9Gt/Gt mice compared to WT animals (P<0.05 for both). Femoral artery endothelial-dependent vasorelaxation was improved in Adcy9Gt/Gt mice (versus WT, P<0.01). Selective pharmacological blockade showed that the nitric oxide, cyclooxygenase, and endothelial-dependent hyperpolarization pathways were all responsible for the improvement of vasodilatation in Adcy9Gt/Gt (P<0.01 for all). Aortic endothelium from Adcy9Gt/Gt mice allowed significantly less adhesion of splenocytes compared to WT (P<0.05). Adcy9Gt/Gt mice gained more weight than WT with the atherogenic diet; this was associated with an increase in whole body adipose tissue volume (P<0.01 for both). Feed efficiency was increased in Adcy9Gt/Gt compared to WT mice (P<0.01), which was accompanied by prolonged cardiac RR interval (P<0.05) and improved nocturnal heart rate variability (P=0.0572). Adcy9 inactivation–induced effects on atherosclerosis, endothelial function, weight gain, adipose tissue volume, and feed efficiency were lost in CETPtgAdcy9Gt/Gt mice (P>0.05 versus CETPtgAdcy9WT). Conclusions: Adcy9 inactivation protects against atherosclerosis, but only in the absence of CETP activity. This atheroprotection may be explained by decreased macrophage accumulation and proliferation in the arterial wall, and improved endothelial function and autonomic tone.


The Cardiology | 2010

Apparent Non-Cited Overlap between Two Published Articles by the Same Group of Authors

Kasper W. ter Horst; Chung-Li Huang; Wen-Yi Yang; Shing-Hong Shi; Andrew Ying-Siu Lee; Victor L. Serebruany; Gad Cotter; Wie-Qiang Huang; Michael Böhm; Magnus Baumhäkel; Felix Mahfoud; Arnljot Tveit; Harald Arnesen; Pål Smith; Vibeke Bratseth; Ingebjørg Seljeflot; Sergei V. Jargin; Rodrigo P. Pedrosa; Sandro Gonçalves de Lima; Luciano F. Drager; Pedro R. Genta; Aline C.S. Amaro; Murillo O. Antunes; Edmundo Arteaga; Charles Mady; Geraldo Lorenzi-Filho; Sammy Elmariah; Nalini M. Rajamannan; David Busseuil; Yanfen Shi

Because review and decision had not been completed for the first article before the second manuscript was submitted, we could not provide a reference for the first paper in the second. (Editors’ note: it might have been appropriate to notify the journal so that the first paper could have been cited in the second, once the first paper had been accepted, but this was not done.) Though the study population was the same for both papers, we studied the effect of homocysteine-induced oxidative stress on endothelial function in coronary slowflow in the first paper, a subject that we continue to believe is not sufficiently related to the effect of thyroid hormone on slow coronary flow, reported in the second paper, to justify their inclusion in a single report. We believe it is common to report unrelated results of interest from single populations.


Atherosclerosis | 2014

The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model

François Roubille; David Busseuil; Yanfen Shi; Walid Nachar; Teodora Mihalache-Avram; Mélanie Mecteau; Marc-Antoine Gillis; Geneviève Brand; Gabriel Théberge-Julien; Mathieu R. Brodeur; Anne-Elen Kernaleguen; Mélania Gombos; Eric Rhéaume; Jean-Claude Tardif

Collaboration


Dive into the Mélanie Mecteau's collaboration.

Top Co-Authors

Avatar

Eric Rhéaume

Montreal Heart Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

David Busseuil

Montreal Heart Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yanfen Shi

Montreal Heart Institute

View shared research outputs
Top Co-Authors

Avatar

David Rhainds

Montreal Heart Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nolwenn Merlet

Montreal Heart Institute

View shared research outputs
Top Co-Authors

Avatar

Eric Thorin

Montreal Heart Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge